Claros | $30,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026) Certified by Founder
Lodge
Braveheart Bio
start up
United States
- San Francisco, California
- 06/11/2025
- Series A
- $185,000,000
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
- Industry Biotechnology Research
- Website https://www.braveheart.bio/
- LinkedIn https://www.linkedin.com/company/braveheart-bio/
Avtal | $24,000,000 | (Mar 20, 2026)
Raven.io | $20,000,000 | (Mar 19, 2026)
Manifold Security | $8,000,000 | (Mar 19, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
xmemory | $4,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)
Obin AI | $7,000,000 | (Mar 19, 2026)
Multiply(US) | $9,500,000 | (Mar 19, 2026)
Respan (formerly Keywords AI) | $5,000,000 | (Mar 19, 2026)